Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable ...

Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...